Prostate Imaging Using MRI +/- Contrast Enhancement (NCT04571840)
A Study Comparing Bi-parametric MRI to Multi-parametric MRI in the Diagnosis of Clinically Significant Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer. This means that we are comparing MRI scans that requires injection of IV contrast (the current standard practice) versus MRI scans that can be performed without IV contrast in the detection of prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic — Rochester, Minnesota
Age range: 18 Years
🧪 Interventions in This Study
- Multiparametric MRI +/- prostate biopsy (DIAGNOSTIC_TEST)
- Biparametric MRI +/- prostate biopsy (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- Mayo Clinic — Rochester, Minnesota
- NYU Langone — New York, New York
- Icahn School of Medicine (Mount Sinai) — New York, New York
- New York Presbyterian Hospital — New York, New York
- Centro de Urologia — Buenos Aires,
- Monash University — Melbourne,
- Peter MacCallum Cancer Centre — Melbourne E.,
- Ghent University Hospital — Ghent,
- Hospital Sírio-Libanês — São Paulo,
- Princess Margaret Cancer Centre — Toronto,
- Herlev and Gentofte Hospital — Copenhagen,
- Helsinki University Hospital — Helsinki,
- Bordeaux Pellegrin University Hospital — Bordeaux,
- CHU Lille — Lille,
- Sorbonne Université — Paris,
- Heinrich Heine University Düsseldorf — Düsseldorf,
- Essen University Hospital — Essen,
- University Hospital Frankfurt — Frankfurt,
- Martini Klinik — Hamburg,
- San Raffaele Hospital — Milan,
- Sapienza University — Rome,
- San Giovanni Battista Hospital — Turin,
- University Hospital of Udine — Udine,
- Radboudumc — Nijmegen,
- Tan Tock Seng Hospital — Novena,
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.